Updated:01/27/2020 15: 05h
Japanese researchers made this Monday the primer heart muscle tissue transplant in which they have been used induced pluripotency cells (iPS), in its search for an alternative to heart transplants.
The operation was done by a team from the University of Osaka (west) led by the cardiovascular surgeon Yoshiki Sawa within the framework of a clinical study to verify effectiveness and safety of treatment in a patient with severe heart failure, whose only current treatment is organ transplantation.
The operation consisted of the transplantation of a sheet of cardiac muscle tissue obtained artificially from iPS cells that were transplanted to the affected areas of the heart.
The experimental treatment will be applied to 10 patients with ischemic heart disease, a disease caused by a narrowing of the coronary arteries that supply blood to the heart, according to the details of the trial collected by the Kyodo news agency.
Another team from Keio University, in Tokyo, is considering an experimental transplant with heart muscle made from iPS cells to check the feasibility of its use in the treatment of dilated heart disease, a dilation of the heart that causes weakness and decreases the ability to pump blood.
The iPS they are a type of cell that It becomes any type of tissue through a process of genetic reprogramming.
The use of this type of cells resolves in principle the ethical dilemma of working with embryonic stem cells which, like the iPS, have the same capacity for cell transformation, and is a very important step for the advancement of regenerative medicine.
IPS cells have already been used in Japan to perform pioneering retinal transplants or to manufacture drugs to treat an extremely rare and genetic origin of bone disease.